Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome?

Rheumatology International

Volumn 34, Issue 2, 2014, Pages 235-241

  Sudzius, Gintaras ^a   Mieliauskaite, Diana ^a   Siaurys, Almantas ^a   Viliene, Rita ^a   Butrimiene, Irena ^a,b   Characiejus, Dainius ^a,b   Dumalakiene, Irena ^a,c  

^a State Research Institute Centre for Innovative Medicine   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

^c VILNIUS GEDIMINAS TECHNICAL UNIVERSITY   (Lithuania)

Author keywords

B cell activating factor; Complement C4; Complement fragment C4d; IgG; Immunoglobulin free light chain; Primary Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LA ANTIBODY; RO ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; SJOEGREN SYNDROME;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMPLEMENT C4; COMPLEMENT C4B; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84895799678     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2885-y     Document Type: Article

References (25)

1. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050:34-39. doi: 10.1196/annals.1313.004
2. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554-558. doi: 10.1136/ard.61.6.554
3. Candon S, Gottenberg JE, Bengoufa D, Chatenoud L, Mariette X (2009) Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity. Ann Rheum Dis 68:1208-1212. doi: 10.1136/ard.2008.095257
4. Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. (2005) Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis 64:1050-1055. doi: 10.1136/ard.2004.030643
5. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, et al. (2007) Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 66:23-27. doi: 10.1136/ard.2006.052159
6. Gottenberg JE, Seror R, Benessiano J, Inamo K, Dieude P, Dubost JJ, et al. (2010) Correlation of Serum BAFF and Markers of B-Cell Activation with Systemic Involvement Assessed by the EULAR Sjögren's Syndrome Disease Activity Index: Results from the ASSESS Prospective Cohort. [abstract]. Arthritis Rheum 62 Suppl 10:1890. doi: 10.1002/art.29655
7. Gottenberg J-E, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, et al. (2013) Serum levels of Beta2-Microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 8:e59868. doi: 10.1371/journal.pone.0059868
8. Zadura AF, Theander E, Blom AM, Trouw LA (2009) Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers. Scand J Immunol 69:374-380. doi: 10.1111/j.1365-3083. 2009.02229.x
9. Ramos-Casals M, Brito-Zerón P, Yagüe J, Akasbi M, Bautista R, Ruano M, et al. (2005) Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology 44:89-94. doi: 10.1093/rheumatology/keh407
10. Theander E, Manthorpe R, Jacobsson LTH (2004) Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 50:1262-1269. doi: 10.1002/art20176
11. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ (2002) Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 13:242-251
12. Smith RN, Brousaides N, Grazette L, Saidman S, Semigran M, Disalvo T, et al. (2005) C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 24:1202-1210
13. Nickeleit V, Mihatsch MJ (2003) Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 18:2232-2239
14. Manzi S, Navratil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, et al. (2004) Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 50:3596-3604
15. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. (2010) EULAR Sjögren's Task Force. EULAR Sjögren's's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 69(6):1103-1109
16. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. (2011) EULAR Sjögren's Task Force. EULAR Sjögren's's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 70(6):968-972
17. Daridon C, Youinou P, Pers JO (2008) BAFF, APRIL, TWE-PRIL: who's who? Autoimmun Rev 7:267-271
18. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K (2005) Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 25:189-201
19. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10
20. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-1319
21. Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, et al. (2009) The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 114:5362-5367
22. Hansen A, Lipsky PE, Dörner T (2007) B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 9:218. doi: 10.1186/ar2210
23. Davids MS, Murali MR, Kuter DJ (2010) Serum free light chain analysis. Am J Hematol 85:787-790
24. Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 46:741-747
25. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812-817